PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 22, 2026Pathology0 citations

Ultrasensitive next-generation sequencing-based clonality assay for disease monitoring in B-cell acute lymphoblastic leukaemia

View Full Paper
ALAnita LeWLWendi LinGLGareth Lamb

Key Points

  • To evaluate the clinical utility of NGS-based measurable residual disease testing for B-cell acute lymphoblastic leukaemia.
  • Implemented NGS-based MRD testing since 2018.
  • Utilized in routine patient care for monitoring.
  • Focused on patients with B-cell acute lymphoblastic leukaemia.
  • Demonstrated clinical utility for disease monitoring.
  • Established effectiveness in detecting measurable residual disease.

Abstract

Background: Next-generation sequencing (NGS)-based measurable residual disease (MRD) testing is increasingly adopted in routine patient care for acute lymphoblastic leukaemia (ALL). We have successfully implemented NGS-based MRD testing since 2018 and demonstrated its clinical utility in B-cell acute lymphoblastic leukaemia (B-ALL).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Le et al. (2026) studied this question.

synapsesocial.com/papers/699a534bfdaf4e3c1268ee30https://doi.org/10.1016/j.pathol.2026.01.243
Ask AI
Helpful
Bookmark
Share
View Full Paper